Protocol Ledger

NCT07062536 · Phase II · RECRUITING

mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line

Interventional Phase II clinical trial protocol NCT07062536 sponsored by Seoul National University Bundang Hospital in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-08-27 Enrollment: 130 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07062536
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)130 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07062536
Protocol FieldVerified Registry Value
NCT IdentifierNCT07062536
Consolidated Lead SponsorSeoul National University Bundang Hospital
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment130 participants (ESTIMATED)
Registered Start Date2025-08-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07062536
Hospital Research SiteLocationSite Profile
Dong-A University HospitalBusan, South KoreaOpen Hospital Dossier ->
Keimyung University, Dongsan hospitalDaegu, South KoreaOpen Hospital Dossier ->
Gachon University Gil Medical CenterIncheon, South KoreaOpen Hospital Dossier ->
Chonnam National University Hwasun HospitalHwasun, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI